SCHEMBL3714770

SCHEMBL3714770

CC(=O)C1=C(O)C(=O)N(CCc2ccccc2)C1c1ccccn1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.67
KDM4E B2RXH2 7/20 0.64
LMNA P02545 3/20 0.64
ALOX15 P16050 2/20 0.60
ALDH1A1 P00352 7/20 0.58
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
MAPT P10636 2/20 0.56
POLB P06746 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.50
HSD17B10 Q99714 1/20 0.50
NPSR1 Q6W5P4 2/20 0.48
RXFP1 Q9HBX9 2/20 0.48
MAPK1 P28482 1/20 0.48
PPARG P37231 1/20 0.48
NCOA2 Q15596 1/20 0.48
NCOR2 Q9Y618 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3713774 0.93 HPGD (0.59) HPGDKDM4ELMNAALOX15ALDH1A1
SCHEMBL3709481 0.82 ALDH1A1 (0.66) HPGDKDM4ELMNAALOX15ALDH1A1
SCHEMBL3709457 0.82 ALOX15 (0.65) HPGDKDM4ELMNAALOX15ALDH1A1
SCHEMBL15731858 0.80 ALDH1A1 (0.73) HPGDKDM4EALOX15ALDH1A1MEN1
SCHEMBL15709460 0.80 ALDH1A1 (0.73) HPGDKDM4EALOX15ALDH1A1MEN1
SCHEMBL3709876 0.79 ALDH1A1 (0.74) HPGDKDM4ELMNAALOX15ALDH1A1
SCHEMBL3705035 0.79 KDM4E (0.66) HPGDKDM4ELMNAALOX15ALDH1A1
SCHEMBL16904821 0.78 KDM4E (0.64) HPGDKDM4ELMNAALOX15ALDH1A1
SCHEMBL3707576 0.78 KDM4E (0.64) HPGDKDM4ELMNAALOX15ALDH1A1
SCHEMBL3705340 0.77 MEN1 (0.78) HPGDKDM4ELMNAALOX15ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO claimed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP claimed
US-20220125760-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) 2022-04-28 US disclosed
EP-3923987-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2021-12-22 EP disclosed
WO-2020165315-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-08-20 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed